SUPPRELIN LA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8062652 | ENDO PHARM | Compositions and methods for treating precocious puberty |
Jun, 2026
(2 years from now) | |
Supprelin La is owned by Endo Pharm.
Supprelin La contains Histrelin Acetate.
Supprelin La has a total of 1 drug patent out of which 0 drug patents have expired.
Supprelin La was authorised for market use on 03 May, 2007.
Supprelin La is available in implant;subcutaneous dosage forms.
Supprelin La can be used as method of treatment of children with central precocious puberty.
The generics of Supprelin La are possible to be released after 16 June, 2026.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | May 03, 2014 |
Drugs and Companies using HISTRELIN ACETATE ingredient
Market Authorisation Date: 03 May, 2007
Treatment: Method of treatment of children with central precocious puberty
Dosage: IMPLANT;SUBCUTANEOUS
More Information on Dosage
SUPPRELIN LA family patents
